Common side-effects of BTK inhibitors (ibrutinib and acalabrutinib) in the treatment of CLL
Alisertib for the treatment of peripheral T-cell lymphoma
Panel discussion on large cell lymphomas: subtypes, patient selection and mutations
Andrew Zelenetz et al.
The first in-human Phase I study of a BET inhibitor for the treatment of NHL
How far are we from a cure for CLL?